• NeuroSense Therapeutics Ltd (NASDAQ: NRSN) has announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD).

• Earlier this week, NeuroSense reported results from a stage III ALS Biomarker study evaluating PrimeC.

• Preliminary results showed that levels of disease-related biomarkers in people with ALS were unchanged, in contrast to a statistically significant decline in biomarkers when PrimeC was administered.

• NeuroSense's biomarker study indicates that CogniC's mechanism of action may effectively target the pathways involved in the disease, such as miRNA dysregulation, lysosomal dysfunction, and impaired autophagy.

• Additionally, hallmarks of AD were detected, such as increased levels of amyloid-β (Aβ) and intracellular aggregates of tau protein among the panel of biomarkers evaluated.

• Preliminary results revealed high levels of TDP-43 in people who suffer from AD compared to the healthy control group.

• NeuroSense says that CogniC has already been shown to impact TDP-43 in a Phase 2a clinical trial biomarker study in amyotrophic lateral sclerosis (ALS).

• NeuroSense is conducting its AD biomarker study using Neuron-Derived Exosomes to observe key alterations in biomarkers.

• Price Action: NRSN shares are up 62.4% at $4.45 during the premarket session on the last check Thursday.

See more from Benzinga

• Universal Health Services Cuts Annual Guidance - Read Why

• The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.